-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Many -X- _ O
Chinese -X- _ B-Intervention
patent -X- _ I-Intervention
medicines -X- _ I-Intervention
( -X- _ I-Intervention
CPMs -X- _ I-Intervention
) -X- _ I-Intervention
have -X- _ O
been -X- _ O
authorized -X- _ O
by -X- _ O
the -X- _ O
Chinese -X- _ O
State -X- _ O
of -X- _ O
Food -X- _ O
and -X- _ O
Drug -X- _ O
Administration -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
the -X- _ O
common -X- _ B-Patient
cold. -X- _ I-Patient
A -X- _ O
number -X- _ O
of -X- _ O
clinical -X- _ O
trials -X- _ O
have -X- _ O
been -X- _ O
conducted -X- _ O
and -X- _ O
published. -X- _ O
However -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
no -X- _ O
systematic -X- _ O
review -X- _ O
or -X- _ O
meta- -X- _ O
analysis -X- _ O
on -X- _ O
their -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
for -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
to -X- _ O
justify -X- _ O
their -X- _ O
clinical -X- _ O
use. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
searched -X- _ O
CENTRAL -X- _ O
, -X- _ O
MEDLINE -X- _ O
, -X- _ O
EMBASE -X- _ O
, -X- _ O
SinoMed -X- _ O
, -X- _ O
CNKI -X- _ O
, -X- _ O
VIP -X- _ O
, -X- _ O
China -X- _ O
Important -X- _ O
Conference -X- _ O
Papers -X- _ O
Database -X- _ O
, -X- _ O
China -X- _ O
Dissertation -X- _ O
Database -X- _ O
, -X- _ O
and -X- _ O
online -X- _ O
clinical -X- _ O
trial -X- _ O
registry -X- _ O
websites -X- _ O
for -X- _ O
published -X- _ O
and -X- _ O
unpublished -X- _ O
randomized -X- _ O
clinical -X- _ O
trials -X- _ O
( -X- _ O
RCTs -X- _ O
) -X- _ O
of -X- _ O
CPMs -X- _ O
for -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
till -X- _ O
31 -X- _ O
March -X- _ O
2013. -X- _ O
Revman -X- _ O
5.2 -X- _ O
software -X- _ O
was -X- _ O
used -X- _ O
for -X- _ O
data -X- _ O
analysis -X- _ O
with -X- _ O
effect -X- _ O
estimate -X- _ O
presented -X- _ O
as -X- _ O
relative -X- _ O
risk -X- _ O
( -X- _ O
RR -X- _ O
) -X- _ O
and -X- _ O
mean -X- _ O
difference -X- _ O
( -X- _ O
MD -X- _ O
) -X- _ O
with -X- _ O
a -X- _ O
95 -X- _ O
% -X- _ O
confidence -X- _ O
interval -X- _ O
( -X- _ O
CI -X- _ O
) -X- _ O
. -X- _ O
RESULTS -X- _ O
: -X- _ O
A -X- _ B-Outcome
total -X- _ I-Outcome
of -X- _ I-Outcome
five -X- _ I-Outcome
RCTs -X- _ I-Outcome
were -X- _ I-Outcome
identified. -X- _ I-Outcome
All -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
RCTs -X- _ I-Outcome
were -X- _ I-Outcome
of -X- _ I-Outcome
high -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
bias -X- _ I-Outcome
with -X- _ I-Outcome
flawed -X- _ I-Outcome
study -X- _ I-Outcome
design -X- _ I-Outcome
and -X- _ I-Outcome
poor -X- _ I-Outcome
methodological -X- _ I-Outcome
quality. -X- _ I-Outcome
All -X- _ I-Outcome
RCTs -X- _ I-Outcome
included -X- _ I-Outcome
children -X- _ I-Outcome
aged -X- _ I-Outcome
between -X- _ I-Outcome
6 -X- _ I-Outcome
months -X- _ I-Outcome
to -X- _ I-Outcome
14 -X- _ I-Outcome
years. -X- _ I-Outcome
Results -X- _ I-Outcome
of -X- _ I-Outcome
individual -X- _ I-Outcome
trials -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
Shuanghuanglian -X- _ I-Outcome
oral -X- _ I-Outcome
liquid -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
4.00 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
2.26 -X- _ I-Outcome
to -X- _ I-Outcome
7.08 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
Xiaoer -X- _ I-Outcome
Resuqing -X- _ I-Outcome
oral -X- _ I-Outcome
liquid -X- _ I-Outcome
( -X- _ I-Outcome
RR -X- _ I-Outcome
1.43 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
1.15 -X- _ I-Outcome
to -X- _ I-Outcome
1.77 -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
higher -X- _ I-Outcome
cure -X- _ I-Outcome
rates -X- _ I-Outcome
compared -X- _ I-Outcome
with -X- _ I-Outcome
antivirus -X- _ I-Outcome
drugs. -X- _ I-Outcome
Most -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
trials -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
report -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ I-Outcome
CPMs -X- _ I-Outcome
was -X- _ I-Outcome
still -X- _ I-Outcome
uncertain. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Some -X- _ O
CPMs -X- _ O
showed -X- _ O
a -X- _ O
potential -X- _ O
positive -X- _ O
effect -X- _ O
for -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
on -X- _ O
cure -X- _ O
rate. -X- _ O
However -X- _ O
, -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
poor -X- _ O
methodology -X- _ O
quality -X- _ O
and -X- _ O
the -X- _ O
defects -X- _ O
in -X- _ O
the -X- _ O
clinical -X- _ O
design -X- _ O
of -X- _ O
the -X- _ O
included -X- _ O
RCTs -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
placebo -X- _ O
controlled -X- _ O
trials -X- _ O
, -X- _ O
the -X- _ O
inappropriate -X- _ O
comparison -X- _ O
intervention -X- _ O
and -X- _ O
outcome -X- _ O
measurement -X- _ O
, -X- _ O
the -X- _ O
confirmative -X- _ O
conclusions -X- _ O
on -X- _ O
the -X- _ O
beneficial -X- _ O
effect -X- _ O
of -X- _ O
CPMs -X- _ O
for -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
could -X- _ O
not -X- _ O
be -X- _ O
drawn -X- _ O
. -X- _ O

